US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

17.74

-0.0600-0.34%

Post-market: 17.800.0600+0.34%19:30 EDT

Volume:28.78K

Turnover:509.79K

Market Cap:104.67M

PE:- -

High:17.93

Open:17.89

Low:17.60

Close:17.80

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:0.55

T/O Rate:0.49%

Dividend:0.71

Dividend Rate:4.03%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.

Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating

Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver

China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating

China's Jiangsu Says it Will Support Pharmaceutical Firms' Global M&A, Licensing

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live

Beone Medicines' First-Half Profit Surges 386% as Core Drug Drives Revenue Past $3.2 Billion

VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

BEONE MEDICINES Reports Strong First-Half Profit Surge of 385.8%

Southbound Capital Insights: Net Buying Hits HK$453 Million, Innovent Bio Faces Heavy Selling After Earnings Surge

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

CICC Maintains Outperform Rating on Innovent Biologics with Target Price Set at HK$118.30

-BUZZ-China's Innovent Biologics Hits All-Time High on H1 Growth

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/KURE/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":17.74,"timestamp":1789156800000,"preClose":17.8,"halted":0,"volume":28778,"hourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"delay":0,"changeRate":-0.00337078651685406,"floatShares":5900168,"shares":5900168,"eps":0,"marketStatus":"Market Closed","change":-0.06,"latestTime":"09-11 16:00:00 EDT","open":17.89,"high":17.93,"low":17.6,"amount":509789.147232,"amplitude":0.018539,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":17.8,"sharesOutstanding":4750002,"nav":17.98,"aum":106101372.73,"dividendRate":0.040293,"bidAskSpread":0.008302,"postHourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"volumeRatio":0.5515710695008692,"impliedVol":0.3113,"impliedVolPercentile":0.6295},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5900168,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5515710695008692,"shares":5900168,"dividePrice":0.7148,"high":17.93,"amplitude":0.018539,"preClose":17.8,"low":17.6,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":17.74,"eps":0,"divideRate":0.040293,"volume":28778,"delay":0,"ttmEps":0,"open":17.89,"prevYearClose":17.04,"prevWeekClose":18.9,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":18.91,"twentyDayClose":18.66,"sixtyDayClose":14.875},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662977171","title":"CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977171","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662977171?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:20","pubTimestamp":1787815224,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (SEHK:1093) is back in focus after reporting half year 2026 results, announcing a higher interim dividend and updating investors on several oncology drug milestones in China.\nThe recent half year 2026 earnings and oncology updates appear to have fed directly into CSPC Pharmaceutical Group’s share price momentum, with a 90 day share price return of 36.85% and a 30 day gain of 14.76% helping lift the stock to HK$9.525. The 3 year total shareholder return of 81.14%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GXDW","RGLO","LU0326950275.SGD","LU0501845795.SGD","FEBU","DCF","LU1226288170.HKD","IE00BZ08YT58.USD","LU0072913022.USD","SG9999004220.SGD","LU1152091754.HKD","LU1328277881.USD","LU1993786604.SGD","LU2039709279.SGD","LU1008478684.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1960683339.HKD","LU0880133367.SGD","01093","DECU","LU1813983027.USD","LU1152091168.USD","BK1521","IE00B031HY20.USD","LU0314109678.HKD","BK1191","BK1515","JOYT","LU0315179316.USD","PMDE","VOTE","LU1226288253.USD","IE0008368742.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU0067412154.USD","LU1226287529.USD","LU1226287875.USD","LU0140636845.USD","VGFPF","IE00B5MMRT66.SGD","LU1226287792.SGD","LU1807302812.USD","KURE","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133409443","title":"Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1133409443","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133409443?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:20","pubTimestamp":1787811619,"startTime":"0","endTime":"0","summary":"Jefferies has released a research report highlighting that INNOVENT BIO (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","HK0000165453.HKD","LU0455707207.USD","LU0502904849.HKD","BK1583","LU1188198961.HKD","LU2242644610.SGD","EWH","LU2488822045.USD","LU2097828714.EUR","LU2097828631.EUR","LU2097828474.EUR","01801","LU0463099449.HKD","LU0244354667.USD","LU0326950275.SGD","LU2097828805.USD","LU1969619763.USD","LU2097828557.USD","KURE","LU2328871848.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773368","title":"Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773368","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773368?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:01","pubTimestamp":1787810460,"startTime":"0","endTime":"0","summary":"0601 GMT - Innovent Biologics' outlicensing drug deals with multinational corporations could remain a key share-price driver, say DBS Group Research analysts in commentary. The Chinese biopharmaceutical company's previous deal with Pfizer in May boosted its stock by around 33% over two months. Innovent likely has around three early stage treatment products that could yield around $955 million in upfront payments, the analysts estimate. The company's balance sheet also remains strong, with net cash of around 16.2 billion yuan as of June, they add. DBS Group Research maintains its buy rating and 144.00 Hong Kong dollar target price. Shares drop 2.55% to HK$107.00.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU0455707207.USD","LU2097828714.EUR","LU1188198961.HKD","01801","HK0000165453.HKD","LU2097828474.EUR","LU0326950275.SGD","LU0244354667.USD","LU2097828805.USD","LU1969619763.USD","LU2097828631.EUR","BK1589","BK1161","LU2242644610.SGD","LU0502904849.HKD","KURE","LU2488822045.USD","BK1583","LU2328871848.SGD","LU0463099449.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727075","title":"China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662727075?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:42","pubTimestamp":1787805765,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's drug regulator accepts Novo Nordisk's application for oral WegovySHANGHAI, Aug 27 (Reuters)-Novo NordiskNOVOb.COsaid on Thursday that China's drug regulator had accepted its applicati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O09E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0170899867.USD","LU2097828474.EUR","BK4588","BK4568","LU0058720904.USD","IE000M9KFDE8.USD","01801","BK1197","IE0002270589.USD","LU0456855351.SGD","SG9999001176.SGD","HK0000165453.HKD","LU0985481810.HKD","LU0463099449.HKD","BK4007","LU2097828557.USD","LU2596442595.SGD","LU1057294990.SGD","LU2242644610.SGD","SG9999001176.USD","LU1894683264.USD","PFE","LU2097828631.EUR","BK4599","SG9999002232.USD","BK4581","LU1894683348.USD","LU0455707207.USD","IE00BLSP4452.SGD","LU0502904849.HKD","LU0321505439.SGD","SG9999011175.SGD","SGXZ57979304.SGD","BK1589","BK1161","IE00BBT3K403.USD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU0868494617.USD","BK1583","SG9999002224.SGD","OZEM","BK4533","00673","KURE","LU2328871848.SGD","LU0321505868.SGD","LU0225771236.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185413400","title":"Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1185413400","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185413400?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:01","pubTimestamp":1787799711,"startTime":"0","endTime":"0","summary":"Akeso (09926) climbed more than 6% during Wednesday's trading session before paring gains, last up 2.34% at HK$96.40 with turnover reaching HK$686 million.On August 26, Akeso announced that its phase...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU1961090484.USD","LU0561508036.HKD","BK0028","LU0348827113.USD","LU0348766576.USD","LU0417516738.SGD","LU0348784397.USD","BK1161","LU2399975544.HKD","09926","KURE","LU0417516571.SGD","BK0276","IE00B543WZ88.USD","LU0348783233.USD","LU0348825331.USD","LU0348767384.USD","LU0540923850.HKD","LU0417516902.SGD","LU2488822045.USD","BK1574","LU1794554557.SGD","LU2476274720.SGD","IE00B5MMRT66.SGD","BK0183","LU2476274308.USD","BK0188","LU0634319403.HKD","LU1720050803.USD","LU0348735423.USD","002736","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662444718","title":"China's Jiangsu Says it Will Support Pharmaceutical Firms' Global M&A, Licensing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662444718","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662444718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:58","pubTimestamp":1787741906,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's Jiangsu says it will support pharmaceutical firms' global M&A, licensingSHANGHAI, Aug 26 (Reuters)-Chinese biotech hub Jiangsu province pledged to support pharmaceutical companies see","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL6N44N0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600276","BK1583","LU2097828557.USD","BK0188","LU2488822045.USD","BK0183","LU0326950275.SGD","LU1064131003.USD","LU0502904849.HKD","LU1146622755.USD","LU2580892862.HKD","LU2328871848.SGD","LU2495084118.USD","LU0405327148.USD","01801","BK1589","LU1781817850.SGD","LU1969619763.USD","LU1997245094.SGD","LU1188198961.HKD","LU0405327494.USD","LU2242644610.SGD","LU0455707207.USD","BK0028","LU0244354667.USD","LU1997244956.HKD","BK0196","BK0060","BK1161","LU1328615791.USD","LU1820825898.SGD","LU1997245177.USD","LU0463099449.HKD","LU1655091616.SGD","LU1064130708.USD","LU1580142542.USD","KURE","LU1255011170.USD","BK0239","LU2097828714.EUR","LU2097828805.USD","LU2148510915.USD","LU2580892789.USD","BK0012","LU2097828631.EUR","LU2289578879.USD","HK0000165453.HKD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718144","title":"CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718144","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718144?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:56","pubTimestamp":1787741807,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  SYS6010 met the pre-specified primary endpoint of progression-free survival as reviewed by the Independent Data Monitoring Committee.The endpoint was reached in a phase III trial testing the product as a monotherapy versus platinum-based chemotherapy for non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.According to the results, the drug candidate's progression-free survival was significantly superior to existing treatment regimens, with high efficacy and favorable safety profile.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0067412154.USD","LU1152091754.HKD","LU1226287792.SGD","LU1993786604.SGD","LU1226288253.USD","IE00B031HY20.USD","IE0008369823.USD","LU1226287875.USD","BK1521","LU1008478684.HKD","LU1813983027.USD","LU2039709279.SGD","BK1191","BK1515","LU0326950275.SGD","LU1328277881.USD","LU1226287529.USD","LU0314109678.HKD","IE0008368742.USD","LU1807302812.USD","LU0880133367.SGD","LU0140636845.USD","01093","LU1226288170.HKD","LU1951186391.HKD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU0072913022.USD","KURE","LU1960683339.HKD","LU0501845795.SGD","LU0315179316.USD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","SG9999004220.SGD","HK0000165453.HKD","LU1152091168.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141434847","title":"Beone Medicines' First-Half Profit Surges 386% as Core Drug Drives Revenue Past $3.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141434847","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141434847?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:44","pubTimestamp":1787741086,"startTime":"0","endTime":"0","summary":"Beone Medicines has delivered a stellar first-half performance for fiscal 2026, with profitability climbing sharply year-on-year and validating the effectiveness of its commercial strategy.According...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU0588546209.SGD","LU1770034418.SGD","BK4588","LU1303224171.USD","LU1719994722.HKD","LU0307460666.USD","BK0239","LU0228659784.USD","BK4526","BK4139","BK1588","BK1161","BK1583","KURE","ONC","BK4585","LU2328871848.SGD","BK1500","LU1251922891.USD","06160","688235","LU0828237510.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662909757","title":"VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2662909757","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662909757?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:34","pubTimestamp":1787740471,"startTime":"0","endTime":"0","summary":"VIVA Biotech H1 profit falls on weaker investment income, FX headwindsOverviewChina-based biopharma services provider's H1 revenue rose 21% yr/yr, driven by CDMO businessNet profit and adjusted non-IF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0DO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0140636845.USD","LU1794554557.SGD","LU1242518931.SGD","01873","LU0128526141.USD","LU0359201612.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU3063872942.SGD","LU0326950275.SGD","LU0359202008.SGD","LU0516422440.USD","KURE","LU0052750758.USD","LU0348735423.USD","BK1610","LU0417516738.SGD","BK1576","LU0029874061.USD","LU0819121731.USD","LU0327786744.USD","LU1880383366.USD","SG9999002463.SGD","LU0181495838.USD","LU1242518857.USD","LU0588546209.SGD","LU0979878070.USD","LU0051755006.USD","BK1521","LU0456827905.SGD","LU0456846285.SGD","LU0823426480.USD","LU0708995583.HKD","LU0039217434.USD","LU0516423174.USD","LU0856984785.SGD","LU2039709279.SGD","LU0307460666.USD","LU1688375341.USD","SG9999002562.SGD","LU0516423091.SGD","LU0417516902.SGD","LU0043850808.USD","BK1589","LU0320764599.SGD","BK1141","LU1720050803.USD","LU0516422952.EUR","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797145","title":"Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797145?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:18","pubTimestamp":1787739506,"startTime":"0","endTime":"0","summary":"Uni-Bio Science H1 revenue falls 12% on pricing changesOverviewHong Kong-listed biopharma firm's H1 2026 revenue fell 12% yr/yr amid pricing adjustmentsNet profit dropped 59% as R+D and commercializat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","IE000MB6IJN5.SGD","FTXH","LU0985320562.USD","IYH","KURE","LU0211327993.USD","LU2133065610.SGD","ABBV","LU2129689605.HKD","XLV","LU0234572021.USD","688331","LU1934455277.USD","IXJ","LU0211328371.USD","BK4588","LU0057025933.USD","LU2347655073.USD","IE000BZT7R73.USD","IE00BSNM7G36.USD","TRUH","01801","BK4533","03692","LU1989772840.SGD","00690","IE00B19Z3581.USD","GLAM","BK1583","IE0009355771.USD","PPH","LU0203347892.USD","BK1191","LU0122379950.USD","LU0820561909.HKD","LU0868494708.USD","MEDX","FHLC","LU0203345920.USD","IE00B2B36J28.USD","VHT","JDOC","SG9999015986.USD","IE0002270589.USD","RXL","BK4581","IE000WAW04H5.SGD","AGNG","IE00BLSP4452.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119638338","title":"CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1119638338","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119638338?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:18","pubTimestamp":1787739482,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","MSS","LU1226287875.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LABU","BK1521","LU0326950275.SGD","BK4588","LU0067412154.USD","BK4113","LU0501845795.SGD","LU1226288253.USD","LU0140636845.USD","LU1328277881.USD","IE00B5MMRT66.SGD","HK0000165453.HKD","LU0314109678.HKD","LU2039709279.SGD","BK1515","LU1152091754.HKD","IE00B543WZ88.USD","LU1226287529.USD","SG9999004220.SGD","KURE","LU1008478684.HKD","BK4585","01093","LU0880133367.SGD","LU1813983027.USD","LU0315179316.USD","IE0008368742.USD","IE0008369823.USD","LU0072913022.USD","LU1226287792.SGD","LU1226288170.HKD","BK1191","LU1807302812.USD","LU1993786604.SGD","LU1960683339.HKD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107537379","title":"BEONE MEDICINES Reports Strong First-Half Profit Surge of 385.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107537379","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107537379?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:16","pubTimestamp":1787739404,"startTime":"0","endTime":"0","summary":"BEONE MEDICINES (06160) has unveiled its interim results for the six months ended June 30, 2026, posting a net profit of $464 million, a substantial year-on-year increase of 385.8%.The company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","LU0588546209.SGD","BK0239","LU0828237510.HKD","LU1969619763.USD","ONC","LU0228659784.USD","BK1583","BK1161","BK1500","BK4588","BK4526","LU1251922891.USD","LU1770034418.SGD","LU1719994722.HKD","BK1588","LU2328871848.SGD","BK4139","06160","KURE","BK4585","LU1303224171.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124902197","title":"Southbound Capital Insights: Net Buying Hits HK$453 Million, Innovent Bio Faces Heavy Selling After Earnings Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1124902197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124902197?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:11","pubTimestamp":1787739111,"startTime":"0","endTime":"0","summary":"On August 26th in the Hong Kong stock market, southbound capital recorded a net buy of HK$453 million. Specifically, the Shanghai-Hong Kong Stock Connect saw a net sell of HK$1.125 billion, while the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","LU2097828631.EUR","LU0326950275.SGD","LU0502904849.HKD","HK0000165453.HKD","BK1583","LU2097828474.EUR","LU0463099449.HKD","LU0244354667.USD","LU0455707207.USD","LU2097828714.EUR","LU2242644610.SGD","LU2097828557.USD","LU2488822045.USD","BK1161","LU2097828805.USD","BK1589","01801","LU1969619763.USD","LU1188198961.HKD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662679768","title":"CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662679768","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662679768?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:11","pubTimestamp":1787739093,"startTime":"0","endTime":"0","summary":"CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancerCSPC Pharmaceutical’s SYS6090 (JMT108) won US FDA Fast Track designation for MSS/pMMR metastatic color","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL2W16sV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","01093","LU0072913022.USD","LU1226288170.HKD","LU0314109678.HKD","IE00B543WZ88.USD","LU0315179316.USD","IE0008369823.USD","LU1226288253.USD","IE0008368742.USD","LU1226287792.SGD","LU1807302812.USD","BK1521","LU1813983027.USD","LU1008478684.HKD","LU1951186391.HKD","IE00B5MMRT66.SGD","BK1191","LU1152091754.HKD","LU0501845795.SGD","IE00B031HY20.USD","LU1328277881.USD","LU0880133367.SGD","IE00BZ08YT58.USD","LU0140636845.USD","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287875.USD","SG9999004220.SGD","IE00BZ08YR35.GBP","LU1993786604.SGD","HK0000165453.HKD","LU0067412154.USD","BK1515","KURE","LU0326950275.SGD","LU1960683339.HKD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115485763","title":"CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1115485763","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115485763?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:10","pubTimestamp":1787739028,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its investigational drug SYS6010 successfully met the predefined primary endpoint of progression-free survival (PFS) in the Phase III clinical study SYNSTAR-01....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1813983027.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","III","LU1152091168.USD","LU0067412154.USD","LU1226287792.SGD","LU0072913022.USD","LU1226287529.USD","LU1226287875.USD","SG9999004220.SGD","IE0008369823.USD","IE00BZ08YT58.USD","BK1521","LU1993786604.SGD","LU0140636845.USD","KURE","LU2039709279.SGD","LU1951186391.HKD","IE00B543WZ88.USD","LU0501845795.SGD","LU0315179316.USD","LU1807302812.USD","LU1960683339.HKD","BK1191","BK1515","LU1008478684.HKD","LU1226288170.HKD","LU1226288253.USD","IE0008368742.USD","LU0880133367.SGD","LU0326950275.SGD","LU0314109678.HKD","IE00BZ08YS42.EUR","HK0000165453.HKD","01093","IE00BZ08YR35.GBP","LU1328277881.USD","LU1152091754.HKD","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797532","title":"CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797532?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:10","pubTimestamp":1787739002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1807302812.USD","LU1008478684.HKD","BK1515","LU1328277881.USD","LU0140636845.USD","LU1813983027.USD","BK1191","LU1226288253.USD","HK0000165453.HKD","LU1152091168.USD","LU1993786604.SGD","BK1521","SG9999004220.SGD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1951186391.HKD","LU1960683339.HKD","LU1226287529.USD","LU1226288170.HKD","01093","IE00BZ08YS42.EUR","IE00B031HY20.USD","LU0314109678.HKD","IE0008368742.USD","LU0501845795.SGD","LU0315179316.USD","LU0072913022.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU2039709279.SGD","LU1226287792.SGD","LU0067412154.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1226287875.USD","IE0008369823.USD","LU0326950275.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662792719","title":"CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662792719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662792719?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:01","pubTimestamp":1787738500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999004220.SGD","LU1152091754.HKD","LU0140636845.USD","LU1226288170.HKD","LU1960683339.HKD","KURE","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0067412154.USD","LU0072913022.USD","LU0326950275.SGD","01093","LU1813983027.USD","LU1226287875.USD","LU0501845795.SGD","IE0008368742.USD","IE00BZ08YR35.GBP","BK1515","BK1521","LU1226287792.SGD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","IE0008369823.USD","BK1191","LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1226288253.USD","HK0000165453.HKD","LU1152091168.USD","LU1951186391.HKD","LU0315179316.USD","LU1993786604.SGD","LU0314109678.HKD","IE00BZ08YT58.USD","LU1328277881.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662796413","title":"CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662796413","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662796413?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:33","pubTimestamp":1787733180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. advanced 1.2% to 9.53 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.6% to 25652.97.This was the stock's third consecutive day of gains.CSPC Pharmaceutical Group Ltd. closed 18% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 2.1%, SSY Group Ltd. rose 5.2%, and United Laboratories International Holdings Ltd. fell 0.8%.Trading volume totaled 190.3 million shares, compared to the 50-day average of 100.7 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","HK0000165453.HKD","IE00B031HY20.USD","LU1226287529.USD","LU1951186391.HKD","LU1960683339.HKD","LU1152091168.USD","LU0314109678.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008368742.USD","LU0072913022.USD","BK1521","IE0008369823.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","LU0315179316.USD","LU1328277881.USD","LU1226288253.USD","IE00BZ08YS42.EUR","01093","LU1008478684.HKD","LU0880133367.SGD","BK1515","LU1813983027.USD","LU1993786604.SGD","BK1191","LU1807302812.USD","LU2039709279.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0326950275.SGD","LU0140636845.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139243882","title":"CICC Maintains Outperform Rating on Innovent Biologics with Target Price Set at HK$118.30","url":"https://stock-news.laohu8.com/highlight/detail?id=1139243882","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139243882?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:11","pubTimestamp":1787724693,"startTime":"0","endTime":"0","summary":"CICC has released a research report stating that it maintains an outperform rating on INNOVENT BIO (01801), keeping its 2026 net profit attributable to shareholders forecast at RMB 2.43 billion....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU1188198961.HKD","LU0455707207.USD","BK1589","LU2328871848.SGD","LU2097828714.EUR","LU2097828631.EUR","BK1583","01801","LU0463099449.HKD","LU0326950275.SGD","EWH","LU0244354667.USD","LU2097828557.USD","BK1161","KURE","LU2488822045.USD","LU2097828474.EUR","LU0502904849.HKD","LU2097828805.USD","HK0000165453.HKD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662540760","title":"-BUZZ-China's Innovent Biologics Hits All-Time High on H1 Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662540760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662540760?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:09","pubTimestamp":1787724588,"startTime":"0","endTime":"0","summary":"-BUZZ-China's Innovent Biologics hits all-time high on H1 growthAdds top pct gainer in key index in third bullet, earnings details in fourth bullet** Shares of China's Innovent Biologics1801.HKjump 12","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N03U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR","LU0455707207.USD","LU2097828714.EUR","LU0326950275.SGD","LU2242644610.SGD","LU2097828557.USD","LU0463099449.HKD","BK1161","BK1589","BK1583","LU1969619763.USD","KURE","01801","LU0244354667.USD","LU0502904849.HKD","LU2488822045.USD","LU2097828631.EUR","LU1188198961.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}